Robotic Bronchoscopy Reaches Deep Into the Lung Periphery: Abu Dhabi Launches AI-Guided Biopsy System

Finding a small nodule on a lung CT scan is only the beginning of the diagnostic journey. When a lesion is located in the lung periphery, conventional bronchoscopy may not easily reach it, and physicians may have difficulty obtaining enough tissue to determine whether it is benign or malignant. Cleveland Clinic Abu Dhabi in the United Arab Emirates recently completed the Middle East’s first robot-assisted bronchoscopy, hoping to bridge the gap between “seeing an abnormality” and “obtaining pathological evidence.”

The procedure uses Johnson & Johnson’s MONARCH platform and the AI-enabled MONARCH QUEST navigation technology. A physician controls a flexible endoscope through the airway’s complex branching network, while the system incorporates intraoperative three-dimensional imaging into navigation and uses algorithms to help locate suspicious lung nodules. Tissue is then collected while the endoscopic view remains continuously displayed. Its role is to help the physician reach the target, not for AI to diagnose cancer independently.

The hospital said the minimally invasive procedure is performed under general anesthesia and typically takes 30 to 75 minutes. It can provide immediate sampling of small or difficult-to-reach nodules without open-chest surgery. In addition to primary lung cancer, biopsy results may be used to distinguish metastatic tumors, benign nodules, tuberculosis, and inflammatory lung diseases. Only by obtaining reliable tissue early can subsequent treatment decisions potentially be brought forward.

The deployment also carries a regional healthcare policy dimension. Abu Dhabi’s health authorities supported the hospital’s introduction of the platform as part of efforts to expand early detection and advanced medical technology. The hospital has also outlined a longer-term vision: if the relevant applications and equipment conditions mature, the robot-guided pathway could potentially be extended in the future to ablation, thermal therapy, or cryotherapy, allowing diagnosis and local treatment to be performed along the same pathway. For now, the focus of the implementation remains diagnostic sampling.

However, “reaching the nodule” does not equal “proving improved patient outcomes.” Johnson & Johnson cited existing robotic bronchoscopy studies and internal technical data to describe the navigation capabilities, but this announcement did not disclose the number of patients in the initial cases, biopsy diagnostic yield, complications, or the prospective validation design for the AI version. Nor did it provide direct comparisons with conventional navigational bronchoscopy or other sampling methods. Whether the algorithm is equally reliable across different imaging equipment, lung anatomy, and levels of operator experience still requires more comprehensive clinical data.

Bronchoscopy itself is also not risk-free. Possible complications include bleeding, infection, low blood oxygen, or pneumothorax, while more severe respiratory and cardiovascular complications may occur in a small number of cases. This first use in the Middle East demonstrates first and foremost that the technology can be integrated into local clinical workflows. Whether it can consistently improve effective sampling rates, reduce repeat examinations, and, at a reasonable cost, translate into earlier treatment and better survival will be the real test in the next phase.